Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13692275 | 1.00 | GABRA1 (0.44) | GABRA1GABRB2SLC6A2SLC6A4TRPA1 | |
| SCHEMBL5988255 | 0.91 | GABRA1 (0.46) | GABRA1GABRB2SLC6A2SLC6A4TRPA1 | |
| SCHEMBL31607250 | 0.83 | PPARA (0.44) | GABRA1GABRB2TRPA1LMNA | |
| SCHEMBL28052525 | 0.82 | GABRA1 (0.40) | GABRA1GABRB2SLC6A2SLC6A4TRPA1 | |
| SCHEMBL1129263 | 0.82 | CYP2D6 (0.41) | GABRA1GABRB2SLC6A2SLC6A4TRPA1 | |
| SCHEMBL4960855 | 0.81 | GABRA1 (0.54) | GABRA1GABRB2SLC6A2SLC6A4ALOX15 | |
| SCHEMBL8678043 | 0.80 | SLC6A4 (0.45) | SLC6A2SLC6A4LMNAALDH1A1POLB | |
| SCHEMBL8677026 | 0.79 | TSHR (0.44) | LMNAALDH1A1POLBHTTL3MBTL1 | |
| SCHEMBL9080018 | 0.78 | TDP1 (0.38) | GABRA1GABRB2SLC6A2SLC6A4TRPA1 | |
| SCHEMBL6464989 | 0.77 | GABRA1 (0.40) | GABRA1GABRB2TRPA1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834233-B1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORP (FI) | 2018-04-25 | — | — | EP | disclosed |
| CN-104220437-B | The adrenoceptor agonists of α 2 | 奥赖恩公司 | 2017-11-10 | — | — | CN | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249127-B2 | Alpha2 adrenoceptor agonists | ORION CORPORATION (FI) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| CN-102036990-B | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP. (US) | 2015-09-30 | — | — | CN | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2015-03-05 | — | — | US | disclosed |
| EP-2834233-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | Orion Corporation (FI) | 2015-02-11 | — | — | EP | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| CN-104220437-A | New alpha2 adrenoceptor agonists | ORION CORP | 2014-12-17 | — | — | CN | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2013150173-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2013-10-10 | — | — | WO | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| CN-102036990-A | Novel tyrosine kinase inhibitors | CHEMBRIDGE CORP | 2011-04-27 | — | — | CN | disclosed |
| EP-2262807-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2C | GABRA1 236/4885GABRB2 209/4885SLC6A2 291/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | GABRA1 2020/4885GABRB2 1987/4885SLC6A2 900/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | GABRA1 2020/4885GABRB2 1987/4885SLC6A2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.